Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Michael
Marks
;
Lucy CK
Bell
;
Imogen
Jones
;
Tommy
Rampling
;
Katharina
Kranzer
;
Stephen
Morris-Jones
;
Sarah
Logan
;
Gabriele
Pollara
;
(2019)
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clinical infectious diseases, 71 (1).
pp. 207-210.
ISSN 1058-4838
DOI: 10.1093/cid/ciz991
;
Lucy CK
Bell
;
Imogen
Jones
;
Tommy
Rampling
;
Katharina
Kranzer
;
Stephen
Morris-Jones
;
Sarah
Logan
;
Gabriele
Pollara
;
(2019)
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clinical infectious diseases, 71 (1).
pp. 207-210.
ISSN 1058-4838
DOI: 10.1093/cid/ciz991
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.
-
picture_as_pdf - Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT.pdf
-
subject - Accepted Version
-
- Available under Creative Commons: Attribution 3.0
Downloads